From: Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
Parameter | P value | |
---|---|---|
Improvement, n (%)a | (n = 129) | |
Yes | 108 (84) | |
No | 21 (16) | |
Headache frequency (overall) | (n = 54) | |
Pre-index, mean (SD) | 22.24 (9.29) | |
Post-index, mean (SD) | 8.24 (7.42) | |
Difference in days, meanb | 14.00 | < 0.001 |
Difference %, mean | 63% | |
MPI (overall) | (n = 74) | |
Pre-index, mean (SD) | 5.47 (3.19) | |
Post-index, mean (SD) | 4.51 (3.34) | |
Difference in days, meanb | 0.96 | 0.014 |
Difference %, mean | 18% |